Mucosal immune response to trivalent live attenuated intranasal influenza vaccine in children

By Boyce T.G.   Gruber W.C.   Coleman-Dockery S.D.   Sannella E.C.   Reed G.W.   Wolff M.   Wright P.F.  

Vaccine, Vol. 18, Iss. 1, 1999-08 ,pp. : 82-88

Elsevier

Access to resources Recommend Favorite

Safety of a trivalent live attenuated intranasal influenza vaccine, FluMist&unknown;, administered in addition to parenteral trivalent inactivated influenza vaccine to seniors with chronic medical conditions

By Jackson L.A.   Holmes S.J.   Mendelman P.M.   Huggins L.   Cho I.   Rhorer J.  

Vaccine, Vol. 17, Iss. 15, 1999-04 ,pp. : 1905-1909

Elsevier

Access to resources Recommend Favorite

Estimation of the efficacy of live, attenuated influenza vaccine from a two-year, multi-center vaccine trial: implications for influenza epidemic control

By Longini I.M.   Halloran M.E.   Nizam A.   Wolff M.   Mendelman P.M.   Fast P.E.   Belshe R.B.  

Vaccine, Vol. 18, Iss. 18, 2000-03 ,pp. : 1902-1909

Elsevier

Access to resources Recommend Favorite

Live attenuated influenza virus vaccines: new options for the prevention of influenza

By Nichol K.L.  

Vaccine, Vol. 19, Iss. 31, 2001-08 ,pp. : 4373-4377

Elsevier

Access to resources Recommend Favorite

Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children

By Halperin S.A.   Smith B.   Mabrouk T.   Germain M.   Trepanier P.   Hassell T.   Treanor J.   Gauthier R.   Mills E.L.  

Vaccine, Vol. 20, Iss. 7, 2002-01 ,pp. : 1240-1247

Elsevier

Access to resources Recommend Favorite